Search Results | Cancer Research | American Association for Cancer Research

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Abstract 1058: Evaluation of a novel class of bifunctional DNA alkylating agent and PARP inhibitor

Sarah Truong, Beibei Zhai, Fariba Ghaidi, Louise Ramos, Jay Joshi, Dennis Brown, Neil Sankar, John Langlands, Jeffrey Bacha, Wang Shen, Mads Daugaard

Cancer Res (2022) 82 (12_Supplement): 1058.

DOI: https://doi.org/10.1158/1538-7445.AM2022-1058

Published: 15 June 2022

View article

Journal Articles

Abstract 1843: Dianhydrogalactitol (VAL-083) for the treatment of glioblastoma multiforme (GBM): Impact of glucose transporters for crossing the blood brain barrier (BBB)

John M. Langlands, Sarath Kanekal, Anne Steino, Armando Mendez, Zoltan Karman, Beata Martonne Toth, Krisztina Heredi-Szabo, Dennis Brown

Cancer Res (2022) 82 (12_Supplement): 1843.

DOI: https://doi.org/10.1158/1538-7445.AM2022-1843

Published: 15 June 2022

View article

Journal Articles

Abstract CT172: Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM

Zhong-ping Chen, Cheng-cheng Guo, Qun-ying Yang, Jia-wei Li, Shao-xiong Wu, John Langlands, Gregory Johnson, Claire Kwan, Sarath Kanekal, Richard Schwartz, Jeffrey Bacha, Anne Steino, Dennis Brown

Cancer Res (2021) 81 (13_Supplement): CT172.

DOI: https://doi.org/10.1158/1538-7445.AM2021-CT172

Published: 01 July 2021

View article

Journal Articles

Abstract CT238: Phase 2 study of dianhydrogalactitol (VAL-083) inpatients with MGMT-unmethylated, bevacizumab-naivepatients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting

Cancer Res (2021) 81 (13_Supplement): CT238.

DOI: https://doi.org/10.1158/1538-7445.AM2021-CT238

Published: 01 July 2021

View article

Journal Articles

Abstract CT137: A pilot pharmacokinetic study of VAL413 in patients with recurrent pediatric solid tumors

James I. Geller, Dennis Brown, Jeffrey Bacha, Neil Sankar, Sarath Kanekal, Mark Leggas, Lars Wagner

Cancer Res (2020) 80 (16_Supplement): CT137.

DOI: https://doi.org/10.1158/1538-7445.AM2020-CT137

Published: 15 August 2020

View article

Journal Articles

Abstract CT154: An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and antitumor activity of once-daily oral treatment with EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration, in patients with advanced cancer

Jeffrey A. Bacha, Dennis Brown, Sarath Kanekal, Ian Nisbet, Neil Sankar, Wang Shen, Helen Wheeler, Kathy Skoff, Zhen Zhong Wang

Cancer Res (2020) 80 (16_Supplement): CT154.

DOI: https://doi.org/10.1158/1538-7445.AM2020-CT154

Published: 15 August 2020

View article

Journal Articles

Abstract 5206: Quantifying DNA-protein crosslinks induced by bifunctional alkylating agents in cultured human leukemia cells

Hailey L. Cerrato, Sam W. Marchant, Allie H. Naccara, Thomas J. LaJoie, Shawnya Michaels, Dennis Brown, Kevin P. Rice

Cancer Res (2020) 80 (16_Supplement): 5206.

DOI: https://doi.org/10.1158/1538-7445.AM2020-5206

Published: 15 August 2020

View article

Journal Articles

Abstract CT116: Phase I/II study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma

Zhong-ping Chen, Chengcheng Guo, Jeffrey Bacha, John Langlands, Anne Steino, Claire Kwan, Sarath Kanekal, Richard Schwartz, Lorena Lopez, Dennis Brown

Cancer Res (2019) 79 (13_Supplement): CT116.

DOI: https://doi.org/10.1158/1538-7445.AM2019-CT116

Published: 01 July 2019

View article

Journal Articles

Abstract CT115: Phase II study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma

Barbara O'Brien, John De Groot, Carlos Kamiya-Matsuoka, Shiao-Pei Weathers, Jeffrey Bacha, Dennis Brown, Anne Steino, John Langlands, Richard Schwartz, Sarath Kanekal, Lorena Lopez, Marta Penas-Prado

Cancer Res (2019) 79 (13_Supplement): CT115.

DOI: https://doi.org/10.1158/1538-7445.AM2019-CT115

Published: 01 July 2019

View article

Journal Articles

Abstract B30: Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of DIPG

Anne Steino, Beibei Zhai, Beibei Zhai, Jeffrey Bacha, Dennis Brown, Shaun Fouse, Joe Costello, Mads Daugaard, Mads Daugaard, Sabine Mueller

Cancer Res (2018) 78 (19_Supplement): B30.

DOI: https://doi.org/10.1158/1538-7445.PEDCA17-B30

Published: 01 October 2018

View article

Journal Articles

Abstract 2985: Molecular mechanisms of dianhydrogalactitol (VAL-083) in cancer treatment

Beibei Zhai, Anne Steino, Jeffrey Bacha, Dennis Brown, Mads Daugaard

Cancer Res (2016) 76 (14_Supplement): 2985.

DOI: https://doi.org/10.1158/1538-7445.AM2016-2985

Published: 15 July 2016

View article

Journal Articles

Abstract 2089: NT113, a potent and selective pan-ErbB inhibitor, is efficacious in vivo and has high brain penetrance.

Wang Shen, Harry Pedersen, Dennis Brown, Jackie Walling, David James, Tomoko Ozawa

Cancer Res (2013) 73 (8_Supplement): 2089.

DOI: https://doi.org/10.1158/1538-7445.AM2013-2089

Published: 15 April 2013

View article

Journal Articles

Abstract 811: VAL083, a novel N7 alkylating agent, surpasses temozolomide activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme

Kaiji Hu, Abbas Fotovati, James Chen, Joanna Triscott, Jeffery Bacha, Dennis Brown, Sandra E. Dunn

Cancer Res (2012) 72 (8_Supplement): 811.

DOI: https://doi.org/10.1158/1538-7445.AM2012-811

Published: 15 April 2012

View article

Journal Articles

Abstract #3279: Omacetaxine induces the rapid loss of anti-apoptotic short-lived proteins in BCR-ABL positive cells

David Segal, Shawnya Michaels, Shaoguang Li, Dennis Brown

Cancer Res (2009) 69 (9_Supplement): 3279.

Published: 01 May 2009

View article

Journal Articles

caBIG compatible software system to elucidate molecular pathways in leukemic cell line (CML) treated with homoharringtonine

Meena Vora, Shawnya Michaels, Jonathan Mansbridge, Saira Singh, Dennis Brown

Cancer Res (2008) 68 (9_Supplement): 1644.

Published: 01 May 2008

View article

Journal Articles

Treatment with homoharringtonine reduces levels of BCR-ABL, Mcl-1, and Hsp90 in leukemia cell lines and the survival of leukemic stem cells

Yaoyu Chen, Yiguo Hu, Shawnya Michaels, David Segal, Dennis Brown, Shaoguang Li

Cancer Res (2008) 68 (9_Supplement): 2275.

Published: 01 May 2008

View article

Journal Articles

Analysis of phosphorylated proteins after treatment of leukemia cell lines with homoharringtonine

Shawnya Michaels, David Segal, William Plunkett, Dennis Brown

Cancer Res (2008) 68 (9_Supplement): 2266.

Published: 01 May 2008

View article

Journal Articles

Analysis of Bcl-2 family protein expression after treatment of leukemia cell lines with homoharringtonine

David Segal, Shawnya Michaels, Adam Craig, William Plunkett, Dennis Brown

Cancer Res (2008) 68 (9_Supplement): 2350.

Published: 01 May 2008

View article

Journal Articles

Design and evaluation of oral delivery dosage forms of homoharringtonine

Dennis Brown, Shawnya Michaels

Cancer Res (2007) 67 (9_Supplement): 4730.

Published: 01 May 2007

View article

Journal Articles

Analysis of transcription factor expression after homoharringtonine treatment

Shawnya Michaels, Dennis Brown, David Segal

Cancer Res (2007) 67 (9_Supplement): 4843.

Published: 01 May 2007

View article

NARROW

Abstract 1058: Evaluation of a novel class of bifunctional DNA alkylating agent and PARP inhibitor

Abstract 1843: Dianhydrogalactitol (VAL-083) for the treatment of glioblastoma multiforme (GBM): Impact of glucose transporters for crossing the blood brain barrier (BBB)

Abstract CT172: Phase 2 clinical trial of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated GBM

Abstract CT238: Phase 2 study of dianhydrogalactitol (VAL-083) inpatients with MGMT-unmethylated, bevacizumab-naivepatients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting

Abstract CT137: A pilot pharmacokinetic study of VAL413 in patients with recurrent pediatric solid tumors

Abstract CT154: An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and antitumor activity of once-daily oral treatment with EO1001, a novel irreversible pan-ErbB inhibitor with promising brain penetration, in patients with advanced cancer

Abstract 5206: Quantifying DNA-protein crosslinks induced by bifunctional alkylating agents in cultured human leukemia cells

Abstract CT116: Phase I/II study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma

Abstract CT115: Phase II study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma

Abstract B30: Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of DIPG

Abstract 2985: Molecular mechanisms of dianhydrogalactitol (VAL-083) in cancer treatment

Abstract 2089: NT113, a potent and selective pan-ErbB inhibitor, is efficacious in vivo and has high brain penetrance.

Abstract 811: VAL083, a novel N7 alkylating agent, surpasses temozolomide activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme

Abstract #3279: Omacetaxine induces the rapid loss of anti-apoptotic short-lived proteins in BCR-ABL positive cells

caBIG compatible software system to elucidate molecular pathways in leukemic cell line (CML) treated with homoharringtonine

Treatment with homoharringtonine reduces levels of BCR-ABL, Mcl-1, and Hsp90 in leukemia cell lines and the survival of leukemic stem cells

Analysis of phosphorylated proteins after treatment of leukemia cell lines with homoharringtonine

Analysis of Bcl-2 family protein expression after treatment of leukemia cell lines with homoharringtonine

Design and evaluation of oral delivery dosage forms of homoharringtonine

Analysis of transcription factor expression after homoharringtonine treatment

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only